Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

First-in-human study of OBT-357 begins in acute myeloid leukemia

Nov. 26, 2014

Primary endpoint met in phase II study of TriMix-DC-MEL melanoma vaccine

Nov. 25, 2014

Amgen terminates all Amgen-sponsored studies of rilotumumab in advanced gastric cancer

Nov. 25, 2014

First clinical data showed that KTN-3379 is well tolerated in advanced solid tumors

Nov. 25, 2014

Novogen identifies lead ATM drug candidate

Nov. 25, 2014

AstraZeneca Canada confirms global lung cancer study of MED-14736

Nov. 21, 2014

New financings support Northwest Biotherapeutics' development of DCVax-L and DCVax-Direct

Nov. 21, 2014

Tumor antigen-targeted IL-15 complex eliminates lymphoma cells

Nov. 18, 2014

Japanese researchers describes anti-NLRR-1 MAbs

Nov. 14, 2014

Advaxis submits IND for phase I/II study of ADXS-HPV and MEDI-4736 for HPV-related cancers

Nov. 14, 2014

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...